Microbot Medical Inc. announced on January 7, 2025, the closing of its previously announced registered direct offering. This offering included the purchase and sale of 4,000,001 shares of common stock at $1.75 per share, along with a concurrent private placement of unregistered short-term series G preferred investment options.
The gross proceeds to the company from this registered direct offering and private placement were approximately $7 million. When combined with approximately $4.8 million raised through its at-the-market (ATM) facility through January 2025, the total gross proceeds reached approximately $11.8 million.
The net proceeds from these offerings are intended to fund the continued development, commercialization, and regulatory activities for the LIBERTY Robotic System. This capital infusion also supports the expansion of additional applications derived from the company's existing IP portfolio and provides working capital for general corporate purposes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.